SEOM-TTCC clinical guideline for nasopharyngeal carcinoma (update 2025)
Por:
Domínguez, AR, Cirauqui, B, Castaño, AG, Cabellos, RA, Maseda, AC, Fernández, BC, Rey, LI, Rubió-Casadevall, J, Arrazubi, V and Mesía, R
Publicada:
1 abr 2026
Ahead of Print:
1 feb 2026
Resumen:
Nasopharyngeal carcinoma is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiotherapy is the cornerstone of locoregional treatment of non-disseminated disease and, in combination with chemotherapy, improves survival rates. In the case of metastatic disease stages, treatment requires platinum/gemcitabine-based chemotherapy, and patients may achieve a long survival time. In these guidelines (updated in 2025), we summarize current evidence and available therapies for the medical management of advanced nasopharyngeal carcinoma.
Filiaciones:
Domínguez, AR:
IBIMA, Reg & Virgen Victoria Univ Hosp, Med Oncol Interctr Unit, Malaga 29010, Spain
:
Catalan Inst Oncol ICO Badalona, IGTP, Med Oncol Dept, B ARGO,CARE, Barcelona, Spain
Castaño, AG:
Hosp Marques Valdecilla, Med Oncol Serv, Santander, Spain
Cabellos, RA:
Hosp Univ Toledo, Med Oncol Dept, Toledo, Spain
Maseda, AC:
Complexo Hosp Univ A Coruna, Med Oncol Serv, Toledo, Spain
Fernández, BC:
Hosp Univ La Paz, Med Oncol Dept, Madrid, Spain
Rey, LI:
Complejo Hosp Univ Ourense, Med Oncol Serv, Orense, Spain
Rubió-Casadevall, J:
Hosp Josep Trueta, Catalan Inst Oncol, Med Oncol Dept, Girona, Spain
Arrazubi, V:
Hosp Univ Navarra, Navarra Inst Hlth Res, Med Oncol Serv, IdiSNA, Pamplona, Spain
:
Catalan Inst Oncol ICO Badalona, IGTP, Med Oncol Dept, B ARGO,CARE, Barcelona, Spain
Green Submitted, hybrid
|